Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities
Present therapeutic regimes have not much improved the survival of patients with metastatic
cancer. Therapeutic cancer vaccines are a form of immunotherapy designed to educate the
immune system to recognise tumor cells as foreign rather than self. New Castle Virus (NDV)
has a long history as a broad system oncolytic that can destroy tumor cells and stimulate
the immune system. Up to 30 patients suffering from recurrent, refractory Glioblastoma
Multiforme, soft an bone sarcomas and disseminated neuroblastoma will be enrolled in this
trial and receive daily doses of NDV at least 5 days a week for a minimum of a year or until
disease progression.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
Measure progression-free survival of patients receiving New Castle Virus
at least 1 year
No
Reuven Or, MD
Principal Investigator
Hadassah Medical Organization
Israel: Ministry of Health
NDV-HUJ-HMO-CTIL
NCT01174537
September 2010
September 2014
Name | Location |
---|